ArticlePLoS biology2019
Changes in chromatin accessibility ensure robust cell cycle exit in terminally differentiated cells.
Article in PLoS biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 71 citations in OpenAlex.
- Molecular mechanisms underlying the maintenance of terminal differentiation in Arabidopsis guard cells.Frontiers in plant science · 2026Review
- tvsfglasso: Time-varying scale-free graphical lasso for network estimation from time-series data.PLoS computational biology · 2025Article
- E2F1 induces a G0-G1 reentry transcriptional program without changing chromatin accessibility.bioRxiv : the preprint server for biology · 2025Article
- A space for time. Exploring temporal regulation of plant development across spatial scales.The Plant journal : for cell and molecular biology · 2025Review
- The impact of cell states on heterochromatin dynamics.The Biochemical journal · 2024Review
- Transcriptional repression and enhancer decommissioning silence cell cycle genes in postmitotic tissues.G3 (Bethesda, Md.) · 2024Article
- Opening and changing: mammalian SWI/SNF complexes in organ development and carcinogenesis.Open biology · 2024Review
- Cell cycle re-entry in the agingbioRxiv : the preprint server for biology · 2024Article
- Transcriptional repression and enhancer decommissioning silence cell cycle genes in postmitotic tissues.bioRxiv : the preprint server for biology · 2024Article
- Temporal dynamics of apoptosis-induced proliferation in pupal wing development: implications for regenerative ability.BMC biology · 2024Article
- Cell cycle perturbation uncouples mitotic progression and invasive behavior in a post-mitotic cell.bioRxiv : the preprint server for biology · 2024Article
- The SWI/SNF nucleosome remodeler constrains enhancer activity during Drosophila wing development.Genetics · 2024Article
- Osmolar Modulation Drives Reversible Cell Cycle Exit and Human Pluripotent Cell Differentiation via NF-κВ and WNT Signaling.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Salidroside enhances 5-fluorouracil sensitivity against hepatocellular carcinoma via YIPF5-induced mitophagy.Frontiers in pharmacology · 2024Article
- Article
- Regulation of early seedling establishment and root development in Arabidopsis thaliana by light and carbohydrates.Planta · 2023Article
- Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K/mTOR, and PAK1-regulated MAPK.Biophysical reviews · 2023Review
- Investigating nanoplastics toxicity using advanced stem cell-based intestinal and lungFrontiers in toxicology · 2023Review
- Noncanonical function of Capicua as a growth termination signal inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Mechanism of activation and the rewired network: New drug design concepts.Medicinal research reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
During terminal differentiation, most cells exit the cell cycle and enter into a prolonged or permanent G0 in which they are refractory to mitogenic signals. Entry into G0 is usually initiated through the repression of cell cycle gene expression by formation of a transcriptional repressor complex called dimerization partner (DP), retinoblastoma (RB)-like, E2F and MuvB (DREAM). However, when DREAM repressive function is compromised during terminal differentiation, additional unknown mechanisms act to stably repress cycling and ensure robust cell cycle exit. Here, we provide evidence that developmentally programmed, temporal changes in chromatin accessibility at a small subset of critical cell cycle genes act to enforce cell cycle exit during terminal differentiation in the Drosophila melanogaster wing. We show that during terminal differentiation, chromatin closes at a set of pupal wing enhancers for the key rate-limiting cell cycle regulators Cyclin E (cycE), E2F transcription factor 1 (e2f1), and string (stg). This closing coincides with wing cells entering a robust postmitotic state that is strongly refractory to cell cycle reactivation, and the regions that close contain known binding sites for effectors of mitogenic signaling pathways such as Yorkie and Notch. When cell cycle exit is genetically disrupted, chromatin accessibility at cell cycle genes remains unaffected, and the closing of distal enhancers at cycE, e2f1, and stg proceeds independent of the cell cycling status. Instead, disruption of cell cycle exit leads to changes in accessibility and expression of a subset of hormone-induced transcription factors involved in the progression of terminal differentiation. Our results uncover a mechanism that acts as a cell cycle-independent timer to limit the response to mitogenic signaling and aberrant cycling in terminally differentiating tissues. In addition, we provide a new molecular description of the cross talk between cell cycle exit and terminal differentiation during metamorphosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.